Dainippon Sumitomo moves into cell therapy through SanBio option deal
This article was originally published in Scrip
Executive Summary
Japan's Dainippon Sumitomo Pharma (DSP) has entered into an option agreement for a novel cell-based therapy for stroke-related disabilities being developed by a private US venture.